Higher-risk patients include those in the dose-escalation phase, those with nausea, vomiting, bloating, abdominal pain, early satiety, or reflux symptoms, those on higher doses with GI side effects, and those with known gastroparesis or other conditions that slow gastric emptying
A 2025 Kinsey Institute survey revealed that more than half of GLP-1 users said the drugs had changed their sex and dating livessometimes for the worse
Downsize the upsell: Appetizers, cocktails, and desserts, while still appealing, may not have room in the GLP-1 patients diet
Discontinuing Glucagon-Like Peptide-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis
Vi kan inte alltid tillmtesg en sdan begran, speciellt om vi fortfarande behver uppgifterna fr ett pgende avtal eller om lagstiftningen krver att vi behller vissa uppgifter
As of February 2026, Eli Lilly plans to submit orforglipron for FDA approval as a diabetes treatment sometime in 2026